The Ebola virus disease outbreak in Tonkolili district, Sierra Leone: a retrospective analysis of the Viral Haemorrhagic Fever surveillance system, July 2014-June 2015.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
01 2019
Historique:
entrez: 15 3 2019
pubmed: 15 3 2019
medline: 28 3 2020
Statut: ppublish

Résumé

In Sierra Leone, the Ebola virus disease (EVD) outbreak occurred with substantial differences between districts with someone even not affected. To monitor the epidemic, a community event-based surveillance system was set up, collecting data into the Viral Haemorrhagic Fever (VHF) database. We analysed the VHF database of Tonkolili district to describe the epidemiology of the EVD outbreak during July 2014-June 2015 (data availability). Multivariable analysis was used to identify risk factors for EVD, fatal EVD and barriers to healthcare access, by comparing EVD-positive vs. EVD-negative cases. Key-performance indicators for EVD response were also measured. Overall, 454 EVD-positive cases were reported. At multivariable analysis, the odds of EVD was higher among those reporting contacts with an EVD-positive/suspected case (odds ratio (OR) 2.47; 95% confidence interval (CI) 2.44-2.50; P < 0.01) and those attending funeral (OR 1.02; 95% CI 1.01-1.04; P < 0.01). EVD cases from Kunike chiefdom had a lower odds of death (OR 0.22; 95% CI 0.08-0.44; P < 0.01) and were also more likely to be hospitalised (OR 2.34; 95% CI 1.23-4.57; P < 0.05). Only 25.1% of alerts were generated within 1 day from symptom onset. EVD preparedness and response plans for Tonkolili should include social-mobilisation activities targeting Ebola/knowledge-attitudes-practice during funeral attendance, to avoid contact with suspected cases and to increase awareness on EVD symptoms, in order to reduce delays between symptom onset to alert generation and consequently improve the outbreak-response promptness.

Identifiants

pubmed: 30869055
pii: S0950268819000177
doi: 10.1017/S0950268819000177
pmc: PMC6518516
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e103

Références

Lancet Glob Health. 2017 Jan;5(1):e80-e88
pubmed: 27955791
MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1168-71
pubmed: 25503921
BMC Med. 2015 Nov 26;13:281
pubmed: 26607790
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4488-93
pubmed: 27035948
Lancet. 2011 Mar 5;377(9768):849-62
pubmed: 21084112
N Engl J Med. 2016 Jan 7;374(1):96-8
pubmed: 26736011
BMC Infect Dis. 2016 Oct 27;16(1):611
pubmed: 27784275
MMWR Suppl. 2016 Jul 08;65(3):35-43
pubmed: 27389614
Clin Infect Dis. 2015 Aug 15;61(4):491-5
pubmed: 25995207
N Engl J Med. 2014 Oct 9;371(15):1418-25
pubmed: 24738640
MMWR Suppl. 2014 Sep 26;63(3):1-14
pubmed: 25254986
Int J Epidemiol. 2016 Feb;45(1):102-16
pubmed: 26589246
Emerg Infect Dis. 2016 Aug;22(8):1403-11
pubmed: 27144428
Lancet. 2015 Aug 1;386(9992):432
pubmed: 26251391
MMWR Morb Mortal Wkly Rep. 2016 Mar 04;65(8):202-5
pubmed: 26938950
EMBO Mol Med. 2014 Dec 30;7(1):17-23
pubmed: 25550396
PLoS One. 2017 May 1;12(5):e0176692
pubmed: 28459838
Lancet Glob Health. 2015 Feb;3(2):e71-2
pubmed: 25617195
Eur J Clin Microbiol Infect Dis. 2017 Apr;36(4):689-695
pubmed: 27888403
Lancet. 1977 Mar 12;1(8011):569-71
pubmed: 65661
Emerg Infect Dis. 2017 Aug;23(8):1380-1383
pubmed: 28726614
Lancet Infect Dis. 2017 Jun;17(6):645-653
pubmed: 28256310
Epidemiol Infect. 2016 May;144(7):1473-81
pubmed: 27029911
J Community Hosp Intern Med Perspect. 2015 Sep 01;5(4):28406
pubmed: 26333864
Emerg Infect Dis. 2016 Sep;22(9):1537-44
pubmed: 27268303
J Virol. 2004 Apr;78(8):4330-41
pubmed: 15047846

Auteurs

Alessandro Miglietta (A)

Epidemiology and Preventive Medicine Units,Central Tuscany Health Authority,Florence,Italy.

Angelo Solimini (A)

Department of Public Health and Infectious Diseases,Faculty of Medicine and Pharmacy,'Sapienza' University of Rome,Rome,Italy.

Ghyslaine Bruna Djeunang Dongho (GB)

Department of Public Health and Infectious Diseases,Faculty of Medicine and Pharmacy,'Sapienza' University of Rome,Rome,Italy.

Carla Montesano (C)

Department of Biology,University of Rome 'Tor Vergata',Rome,Italy.

Giovanni Rezza (G)

Department of Infectious Diseases,Istituto Superiore di Sanità,Rome,Italy.

Vincenzo Vullo (V)

Department of Public Health and Infectious Diseases,Faculty of Medicine and Pharmacy,'Sapienza' University of Rome,Rome,Italy.

Vittorio Colizzi (V)

Department of Biology,University of Rome 'Tor Vergata',Rome,Italy.

Gianluca Russo (G)

Department of Public Health and Infectious Diseases,Faculty of Medicine and Pharmacy,'Sapienza' University of Rome,Rome,Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH